Clinical Trial Update: Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating switching virologically suppressed HIV-1 participants from ATRIPLA to MK-1439A (doravirine/tenofovir disoproxil fumarate/lamivudine) to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• MK-1439A (doravirine/tenofovir disoproxil fumarate/lamivudine) (doravirine/tenofovir disoproxil fumarate/lamivudine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1, Central Nervous System | Phase 2 | Status: COMPLETED | Results posted: 2019-08-29